Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · IEX Real-Time Price · USD
14.13
+0.68 (5.06%)
At close: Aug 12, 2022 4:00 PM
14.53
+0.40 (2.83%)
After-hours:
Aug 12, 2022 7:54 PM EDT
Income Statement (Annual)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|
| Revenue
|
0 | 7.87 | 22.5 | 9.73 | 8.36 | 6.36 | 2.99 |
| Revenue Growth (YoY)
|
- | -65.02% | 131.14% | 16.43% | 31.55% | 112.83% | - |
| Gross Profit
|
0 | 7.87 | 22.5 | 9.73 | 8.36 | 6.36 | 2.99 |
| Selling, General & Admin
|
19.64 | 17.42 | 10.97 | 7.45 | 4.68 | 3.43 | 2.73 |
| Research & Development
|
55.91 | 25.74 | 43.71 | 38.29 | 29.83 | 21.99 | 6.85 |
| Other Operating Expenses
|
0 | 46.91 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
|
75.55 | 90.07 | 54.68 | 45.74 | 34.51 | 25.43 | 9.58 |
| Operating Income
|
-75.55 | -82.2 | -32.18 | -36.01 | -26.15 | -19.07 | -6.59 |
| Other Expense / Income
|
-3.28 | -7.39 | -0.35 | -1.47 | -0.66 | -0.95 | 0 |
| Pretax Income
|
-72.27 | -74.81 | -31.83 | -34.53 | -25.49 | -18.12 | -6.59 |
| Net Income
|
-72.27 | -74.81 | -31.83 | -34.53 | -25.49 | -18.12 | -6.59 |
| Preferred Dividends
|
0 | 104.4 | 0 | 0.02 | 0.07 | 0.06 | 0.04 |
| Net Income Common
|
-72.27 | -179.21 | -31.83 | -34.55 | -25.56 | -18.19 | -6.64 |
| Shares Outstanding (Basic)
|
39 | 11 | 8 | 6 | 3 | 3 | 3 |
| Shares Outstanding (Diluted)
|
39 | 11 | 8 | 6 | 3 | 3 | 3 |
| Shares Change
|
249.52% | 45.42% | 22.43% | 144.27% | 0.02% | - | - |
| EPS (Basic)
|
-1.87 | -16.17 | -4.18 | -5.56 | -10.04 | -7.12 | -2.60 |
| EPS (Diluted)
|
-1.87 | -16.17 | -4.18 | -5.56 | -10.04 | -7.12 | -2.60 |
| Free Cash Flow Per Share
|
-1.56 | -3.21 | -5.43 | -5.31 | -10.50 | -8.62 | 6.17 |
| Gross Margin
|
- | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Margin
|
- | -1044.30% | -143.00% | -369.90% | -312.80% | -300.10% | -220.80% |
| Profit Margin
|
- | -2276.80% | -141.50% | -354.90% | -305.70% | -286.20% | -222.20% |
| Free Cash Flow Margin
|
- | -451.40% | -183.80% | -339.40% | -319.90% | -345.40% | 526.50% |
| EBITDA
|
-72.13 | -74.09 | -30.54 | -33.21 | -24.32 | -17.29 | -6.41 |
| EBITDA Margin
|
- | -941.30% | -135.70% | -341.20% | -290.90% | -272.10% | -214.80% |
| Depreciation & Amortization
|
0.15 | 0.72 | 1.29 | 1.32 | 1.17 | 0.83 | 0.18 |
| EBIT
|
-72.27 | -74.81 | -31.83 | -34.53 | -25.49 | -18.12 | -6.59 |
| EBIT Margin
|
- | -950.40% | -141.50% | -354.80% | -304.90% | -285.20% | -220.80% |
Source: Financials are provided by
Nasdaq Data Link
and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).